TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05768893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm
Description: Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG Laser 2940nm
Description: Warts with this intervention treated only with the Er:YAG laser.
Study: NCT05722977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib + envafolimab
Description: Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
Study: NCT06396988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novamin application
Description: Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parodontax application
Description: Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
Study: NCT04835688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmyringeal ventilation tube insertion
Description: In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-treatment
Description: For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
Study: NCT05369793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
Study: NCT04745390

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
Study: NCT05538429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinal plane combined with serratus anterior plane block
Description: The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinal plane combined with serratus anterior plane block
Description: The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
Study: NCT05024890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splash WASH in Schools programme (Project WISE)
Description: The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide
Study: NCT06009198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron folate tablets
Description: Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
Study: NCT05241288

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol eMDPI DS
Description: Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)
Study: NCT04912661

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: intravenous iron carboxymaltose
Study: NCT04992299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: 6-week mindfulness-based intervention of 6 weekly 1 hour group sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: 6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: 6-week health education didactic program of 6 weekly 1 hour group sessions
Study: NCT05312268

Intervention type: DRUG
Group type: OTHER
Intervention: Rasburicase
Description: Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.

Intervention type: DRUG
Group type: OTHER
Intervention: Rasburicase
Description: Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
Study: NCT04831593

Intervention type: OTHER
Intervention: Group El
Description: Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.

Intervention type: OTHER
Intervention: Group Em
Description: Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
Study: NCT05109611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray with isotonic saline
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
Study: NCT05885568

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: Blood sampling from healthy volunteers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Blood sampling from healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drone transportation
Description: drone transportation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: car transportation
Description: car transportation
Study: NCT05305976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The 8 week exercise program with telerehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The 8 week exercise program with telerehabilitation
Study: NCT05310760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit C
Description: Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
Study: NCT06280937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearing a tie
Description: Individuals in the study group will be asked to wear a tie during one office working day.
Study: NCT06184919

Intervention type: OTHER
Intervention: Process Mapping: Observations
Description: Direct observations of the POSH clinic visit.

Intervention type: OTHER
Intervention: Process Mapping: Observations
Description: Direct observations of the POSH clinic visit.

Intervention type: OTHER
Intervention: Process Mapping: Interviews
Description: Semi-structured interviews of patients and providers involved in the POSH clinic.

Intervention type: OTHER
Intervention: Process Mapping: Interviews
Description: Semi-structured interviews of patients and providers involved in the POSH clinic.

Intervention type: OTHER
Intervention: Process Mapping: Focus Group
Description: Focus group of providers and staff who conduct the POSH clinic.

Intervention type: OTHER
Intervention: Participatory Design
Description: Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups.

Intervention type: OTHER
Intervention: Participatory Design
Description: Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups.
Study: NCT04111627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
Study: NCT06337994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
Study: NCT04111627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
Study: NCT06456190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training in Active Recovery (STAR) Video
Description: a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
Study: NCT05228704

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: activities in the Botanical Garden or in urban
Description: activities in the Taipei Botanical Garden or in Urban

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activities in the Botanical Garden or in urban
Description: activities in the Taipei Botanical Garden or in Urban
Study: NCT05739253

Intervention type: PROCEDURE
Intervention: Transcatheter aortic valve replacement
Description: All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
Study: NCT04930419

Intervention type: DEVICE
Group type: OTHER
Intervention: Videolaryngoscopy group
Description: Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care

Intervention type: DEVICE
Group type: OTHER
Intervention: Direct laryngoscopy group
Description: Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
Study: NCT06456190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training in Active Recovery (STAR) Video
Description: a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training in Active Recovery (STAR) Video
Description: a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Skills Training in Active Recovery (TextSTAR) program
Description: a 3-week daily text program that includes supportive/empowering messages along with brief coping tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Skills Training in Active Recovery (TextSTAR) program
Description: a 3-week daily text program that includes supportive/empowering messages along with brief coping tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
Study: NCT05194293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT05702723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-3RP
Description: 9 sessions of mind-body group treatment program via Zoom platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: 14-week group-based, online support group through CancerCare.org.
Study: NCT06138067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity approach
Description: PEM, cancer center support services material, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the participants appointment with the medical oncologist. If enrolled in a clinical trial, the patient navigator will call the participant biweekly, or more often if they are working to resolve any needs identified in the needs assessment) until the participant is successfully enrolled in the therapeutic clinical trial. The patient navigator will call the participant once weekly for 4 weeks, or less than 4 weeks in other cases including withdrawal from the clinical trial or this navigation study, disease progression, or death. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity approach
Description: The participant will receive PEM, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the appointment with the medical oncologist. The patient navigator will call the participant 4 weeks after enrollment on the trial. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
Study: NCT05643638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)
Description: Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
Study: NCT05401604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate probiotic beer consumption
Description: Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Moderate normal beer consumption
Description: Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
Study: NCT04259060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxocobalamin with Butyrate
Description: In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2.
Study: NCT05643638

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product is identical to CYP-001, except that it contains no active agent
Study: NCT04259060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with Butyrate
Description: In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.
Study: NCT05643638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
Study: NCT06147791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External scrotal drainage
Description: Application of external scrotal drainage during three-component penile prosthesis placement
Study: NCT06534437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1703
Description: MEN1703 is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glofitamab
Description: Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Study: NCT05284656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Pentoxifylline 400 MG and Folic Acid
Description: drugs used to delay progression of chronic kidney disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: drugs used to delay progression of chronic kidney disease
Study: NCT06332729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: universal exercis unit
Description: Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
Study: NCT05284656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG
Description: drugs used to delay progression of chronic kidney disease
Study: NCT06332729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: functional electrical stimulation
Description: Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement